Genprex, Inc. 8-K

What Happened
Genprex, Inc. (GNPX) filed a Form 8‑K on April 21, 2026 announcing a new Sponsored Research Agreement (SRA) with The University of Texas MD Anderson Cancer Center to study biomarkers that may predict patient response to its lead gene therapy candidate, REQORSA (quaratusugene ozeplasmid). The company also furnished an investor presentation (Exhibit 99.1) that may be used in meetings and is posted on the company website. Preclinical collaborators have identified TROP2 and PTEN as potential biomarkers that could help refine patient selection for Genprex’s ongoing clinical programs.

Key Details

• Filing date: April 21, 2026; investor presentation furnished as Exhibit 99.1.
• Research focus: biomarkers TROP2 (transmembrane glycoprotein) and PTEN (tumor suppressor) to predict response to REQORSA.
• Clinical program status: Acclaim‑1 (REQORSA + AstraZeneca’s Tagrisso) is in Phase 2a expansion after Phase 1 dose escalation; Acclaim‑3 (REQORSA + Genentech’s Tecentriq) is in Phase 2 expansion after Phase 1 dose escalation.
• Phase 1 results noted: no dose‑limiting toxicities (DLTs); Acclaim‑1 had 3 of 12 patients with prolonged progression‑free survival and one patient with a partial response maintained through ~60 courses (~42 months); Acclaim‑3 had one patient with an unconfirmed partial remission after 24 cycles continuing >18 months.

Why It Matters
A new SRA with a leading cancer center signals continued investment in biomarker research that could improve patient selection and potentially increase the effectiveness of REQORSA in ongoing trials. For investors, the filing confirms continued clinical progress (advancing to Phase 2 expansions) and highlights early signs of clinical activity, while also including standard forward‑looking statement cautions about risks and uncertainties.